Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | JCXH-211 |
Synonyms | |
Therapy Description |
JCXH-211 consists of a self-replicating RNA (srRNA) for IL-12 contained within a lipid nanoparticle, which potentially results in enhanced antitumor immune response and induction of a cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JCXH-211 | JCXH 211|JCXH211 | JCXH-211 consists of a self-replicating RNA (srRNA) for IL-12 contained within a lipid nanoparticle, which potentially results in enhanced antitumor immune response and induction of a cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05539157 | Phase I | JCXH-211 | Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | Active, not recruiting | USA | 0 |